Toronto, ON – Dalton Chemical Laboratories, a privately owned Canadian pharmaceutical services provider, has completed Phase III of its facilities expansion.
The $1.4 million expansion includes a peptide production laboratory, a microbiology laboratory, a QA sampling suite, an oligonucleotide production suite, a back-up generator and a UPS system.
“We are pleased to continue to add to our world-class research and manufacturing facilities for our Canadian and worldwide customer base,” says Peter Pekos, president and CEO. "By providing medicinal chemistry, integrated GMP synthesis and sterile fill in the same facility, Dalton can now reduce the development time for our clients dramatically."
The peptide laboratory accommodates a variety of peptide synthesis, purification and analysis equipment from micro-scale to 100g production scale. The space is equipped with two walk-in fume hoods, a bench top fume hood and a separate, negatively pressured solvent removal room.
The company’s in-house microbial monitoring capabilities have been expanded with the new microbiology laboratory, which is outfitted for biohazard safety level 2 conditions with a variety of incubators and biohazard hoods to ensure safe handling and processing.
"Our oligonucleotide production suite is equipped with the latest technology that allows small to large-scale oligo production and purification capabilities," he says. "Our equipment includes 4 AKTA oligopilots each capable of producing 50g of oligo per run.
The addition of a regulated QA sampling suite equipped with the latest monitoring and safety devices is a key step in Dalton’s GMP compliance.
A back-up generator that can support a facility twice the facility’s current size was installed to ensure that Dalton’s production will continue during any main grid malfunctions. Installation of a new uninterruptible power supply ensures that all critical GMP and analytical equipment at the facility is protected from any power fluctuation.